[HTML][HTML] Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) …
Abstract Abstract 114 Background: Romidepsin is a potent HDAC inhibitor approved by the
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …
FDA for patients (pts) with cutaneous T-cell lymphoma who have received at least 1 prior …
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Purpose Romidepsin is a structurally unique, potent class 1 selective histone deacetylase
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …
Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL).
Abstract Abstract 1657 Poster Board I-683 Background The histone deacetylase (HDAC)
inhibitors are a class of epigenetic agents undergoing clinical testing. HDAC inhibitors …
inhibitors are a class of epigenetic agents undergoing clinical testing. HDAC inhibitors …
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Background Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …
[HTML][HTML] Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).
Background: The histone deacetylase (HDAC) inhibitors are a class of epigenetic agents
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …
Romidepsin for the treatment of peripheral T-cell lymphoma
SP Iyer, FF Foss - The oncologist, 2015 - academic.oup.com
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas
associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert …
associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert …
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
F Foss, B Pro, H Miles Prince, L Sokol… - Cancer …, 2017 - Wiley Online Library
Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive non‐Hodgkin
lymphomas typically associated with poor prognosis. Most patients with PTCL receive …
lymphomas typically associated with poor prognosis. Most patients with PTCL receive …
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
D Maruyama, K Tobinai, M Ogura, T Uchida… - International journal of …, 2017 - Springer
This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Background Achievement of durable responses in patients with relapsed/refractory
peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few …
peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few …
[HTML][HTML] Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma
Background: Peripheral T-cell lymphoma (PTCL) is an aggressive form of non-Hodgkin
lymphoma (NHL) that is typically associated with a poor prognosis. Romidepsin is a histone …
lymphoma (NHL) that is typically associated with a poor prognosis. Romidepsin is a histone …